脑性瘫痪的外显子组测序诊断率及对遗传检测指南的启示:系统综述与荟萃分析
该系统综述与荟萃分析纳入13项研究、共2612例脑性瘫痪患者,评估外显子组或基因组测序的诊断率。总体诊断率为31.1%(95%CI 24.2%-38.6%),儿童人群为34.8%,使用排除标准筛选患者的研究为42.1%。结论认为脑性瘫痪的遗传诊断率与其他推荐外显子组测序的神经发育障碍相似,支持将脑性瘫痪纳入现有外显子组测序推荐。
要点
- 脑性瘫痪患者外显子组/基因组测序总体诊断率为31.1%(95%CI 24.2%-38.6%)。
- 儿童人群诊断率34.8%(95%CI 28.3%-41.5%),高于成人人群的26.9%(95%CI 1.2%-68.8%)。
- 使用排除标准筛选患者的研究诊断率为42.1%,高于未使用者20.7%。
核心结论
- 脑性瘫痪的遗传诊断率与其他推荐外显子组测序的神经发育障碍相似,支持将脑性瘫痪纳入现有外显子组测序推荐。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed 2013年至2022年发表的研究,纳入13项在至少10例脑性瘫痪患者中行外显子组或基因组测序的研究,共2612例患者。
主要发现
- 总体诊断率为31.1%(95%CI 24.2%-38.6%),研究间异质性I2=91%。
- 儿童人群诊断率为34.8%(95%CI 28.3%-41.5%),成人人群为26.9%(95%CI 1.2%-68.8%)。
- 使用排除标准筛选患者的研究诊断率为42.1%(95%CI 36.0%-48.2%),未使用者为20.7%(95%CI 12.3%-30.5%)。
关键数值与推荐
- 纳入标准:在至少10例脑性瘫痪患者中行外显子组或基因组测序的研究。
- 排除标准:少于10例个体的研究及报告其他遗传检测变异的研究。
- 主要结局为汇总诊断率(致病/可能致病变异率),按人群年龄和患者选择排除标准的使用进行亚组分析。
临床怎么用
- 对于脑性瘫痪患者,可考虑将外显子组测序作为诊断评估的一部分,尤其适用于儿童人群及经排除标准筛选的患者。
局限性
- 研究间异质性较高(I2=91%),成人亚组置信区间宽,解读需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Exome sequencing is a first-tier diagnostic test for individuals with neurodevelopmental disorders, including intellectual disability/developmental delay and autism spectrum disorder; however, this recommendation does not include cerebral palsy. OBJECTIVE: To evaluate if the diagnostic yield of exome or genome sequencing in cerebral palsy is similar to that of other neurodevelopmental disorders. DATA SOURCES: The study team searched PubMed for studies published between 2013 and 2022 using cerebral palsy and genetic testing terms. Data were analyzed during March 2022. STUDY SELECTION: Studies performing exome or genome sequencing in at least 10 participants with cerebral palsy were included. Studies with fewer than 10 individuals and studies reporting variants detected by other genetic tests were excluded. Consensus review was performed. The initial search identified 148 studies, of which 13 met inclusion criteria. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 investigators and pooled using a random-effects meta-analysis. Incidence rates with corresponding 95% CIs and prediction intervals were calculated. Publication bias was evaluated by the Egger test. Variability between included studies was assessed via heterogeneity tests using the I2 statistic. MAIN OUTCOMES AND MEASURES: The primary outcome was the pooled diagnostic yield (rate of pathogenic/likely pathogenic variants) across studies. Subgroup analyses were performed based on population age and on the use of exclusion criteria for patient selection. RESULTS: Thirteen studies were included consisting of 2612 individuals with cerebral palsy. The overall diagnostic yield was 31.1% (95% CI, 24.2%-38.6%; I2 = 91%). The yield was higher in pediatric populations (34.8%; 95% CI, 28.3%-41.5%) than adult populations (26.9%; 95% CI, 1.2%-68.8%) and higher among studies that used exclusion criteria for patient selection (42.1%; 95% CI, 36.0%-48.2%) than those that did not (20.7%; 95% CI, 12.3%-30.5%). CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, the genetic diagnostic yield in cerebral palsy was similar to that of other neurodevelopmental disorders for which exome sequencing is recommended as standard of care. Data from this meta-analysis provide evidence to support the inclusion of cerebral palsy in the current recommendation of exome sequencing in the diagnostic evaluation of individuals with neurodevelopmental disorders.
引用
- Gonzalez-Mantilla PJ, Hu Y, Myers SM, et al. Diagnostic Yield of Exome Sequencing in Cerebral Palsy and Implications for Genetic Testing Guidelines: A Systematic Review and Meta-analysis. JAMA Pediatr. 2023. PMID: 36877506. doi:10.1001/jamapediatrics.2023.0008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。